medical research foundation emerging leaders

• Annual Report
• Your donation - the difference it makes
• Join our team
• Our research
• Information for researchers
• Apply for funding
• Make a donation
• Leave a gift in your Will
• Find an event
• Get involved
• Our promise to you
• Donate in memory
• Corporate partnerships
• News and Events

2024 Emerging Leaders Prize

Last updated.

Our Emerging Leaders Prize on the Impact of Climate Change on Health is open for applications. This funding call will close at 12:00 on Tuesday 16 April 2024.

This year's Emerging Leaders Prize will recognise scientists who are making an impact with their research into the health impacts of climate change in the UK.

We are inviting applications from outstanding UK-based researchers who have shown how health outcomes in the UK are being impacted by climate change , and demonstrated their potential to be research leaders of the future.

Applications from researchers whose work has not been focused solely on UK contexts will be considered if it is relevant or can be applied to UK health.

The prize will allow me to take my research to the next level, and build a team that will go on to tackle the biggest challenges that we face in liver disease and viral hepatitis over the next 25 years.

What is the Emerging Leaders Prize?

Each year, our Emerging Leaders Prize celebrates the achievements of researchers working on a different research theme. The prize funding provides a springboard for the winners’ careers and ensures they can continue to tackle key health challenges – both now and long into the future.

In previous years, the prize has recognised researchers working in the fields of hepatitis , lupus , COVID-19 , pain , antimicrobial resistance , and adolescent mental health .

The funding is flexible , meaning that the winners decide how best to use it. This could mean spending time in a lab overseas, buying a cutting-edge piece of technology for their research, or investing in their personal career development.

Who can apply?

The prize is open to UK-based researchers undertaking research into the impact of climate change on health in the UK. Applicants must hold a PhD, DPhil or MD and be based at eligible institutions (UK HEIs, Research Council research institutes, hospitals, GP practices and other clinics, and other independent research organisations).

Applicants must be in the process of transitioning (or have recently transitioned) to an independent research position. They should demonstrate an upward trajectory across their past career and a track-record of nationally-competitive research, an ability to manage an independent research group, and have clear plans to develop into an internationally-recognised leader in the field.

Which fields of research will the prize cover?

Applicants may have conducted research related to (but not limited to) the following scientific areas in relation to climate change in the UK: non-infectious health outcomes and infectious disease, UK health policy and health systems, the epidemiology of health conditions, development and implementation of treatments for climate-change related health conditions, and the impacts on mental health and well-being.

This is not an exhaustive list and all areas related to the impact of climate change on health in the UK will be considered . Applicants will be required to demonstrate their track record in research on the impact of climate change on health and have the potential to become a leader in their field in the future.

Funding available

Up to £200,000 is available for the 2024 Emerging Leaders Prize. A top prize of £100,000 will be awarded and smaller prizes of various amounts for second place and highly commended candidates.

The research supported in this competition is possible thanks to the support of our generous donors.

Expert Panel

Applications will be reviewed by an expert panel made up of core panel members with experience in assessing career development and fellowship awards, and specialist members with experience in research areas relevant to the climate change and health. The Panel will be chaired by the Chair of our Board of Trustees, Professor Paul Moss OBE .

• Deadline for submission: 12:00 Tuesday 16 April 2024
• Shortlisting notification: July 2024
• Interview panel meeting: 16 September 2024
• Funding decision and feedback: September/October 2024
• Prize-giving event: 28 November 2024

How to apply

All applications must be submitted via our online grants management system .

Please see here the 2024 Guidelines for Applicants.

Guidelines for applicants

Read the full guidelines on applying

The Medical Research Foundation is committed to making this application accessible to all by offering assistance where needed.

Please do not hesitate to get in touch with the Research Team if you have any questions or concerns about the application or interview processes:

Email: [email protected]

Tel: 020 4581 2402

Terms and Conditions of Award

Awards funded through this competition will follow standard Medical Research Foundation terms and conditions. The terms and conditions spell out the responsibilities of the Principal Investigator and the Lead Research Organisation. The Principal Investigator and the Lead Research Organisation are required to indicate their formal acceptance of the proposal, their acceptance of the terms and conditions of an award, and the approval of the salaries and resources sought in the application.

The Medical Research Foundation may add additional conditions to a grant award to reflect the particular circumstances and requirements of the funding, or the nature of a particular award. Acceptance of an award constitutes acceptance of both the core conditions and any additional conditions. The Medical Research Foundation reserves the right to vary these terms and conditions.

Get in touch

If you have any questions, please get in touch with our Research Team

Promoting partnerships for the planet

Emerging Leaders Prize recognises future leaders in hepatitis research

£2.7 million for new research into health impacts of climate change

Emerging Leaders Prize recognises future leaders in lupus research

University  news

The latest headlines from Glasgow Caledonian University and details of how to contact one of our specialists.

Liver disease expert wins Medical Research Foundation Emerging Leaders First Prize

The Medical Research Foundation has awarded Glasgow Caledonian University’s Dr Hamish Innes the coveted Emerging Leaders First Prize, recognising him as a future leader in hepatitis research.

Dr Innes, a Research Fellow in the School of Health and Life Sciences’ Research Centre for Health (ReaCH), was awarded £100,000 to further his life-saving research into hepatitis C antiviral therapy.

He beat Oxford and Glasgow universities to the top prize. Dr Azim Ansari, from the University of Oxford, won second prize and Dr Joe Grove, from the University of Glasgow, was highly commended.

Hepatitis is an inflammation of the liver. There are five main strains of the hepatitis virus, referred to as types A, B, C, D and E. In particular, types B and C (HBV and HCV) are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths.

An estimated 354 million people worldwide live with HBV or HCV, and better options for diagnosing and treating hepatitis are needed to help prevent the 1.4m deaths that occur each year worldwide.

W hile existing treatments can lead to a cure, the prospect of life-long antiviral therapy can lead to a number of complex challenges.

The Medical Research Foundation awarded Dr Innes first prize for his “outstanding” research into tackling both viral and autoimmune hepatitis at a special prize-winners award ceremony in London on Wednesday, November 22.

The Emerging Leaders Prize awards are designed to support research leaders of the future with flexible funding that can be used to enhance career development as well as their research.

With expertise in epidemiology, statistics, genetics and analysis of linked health data, Dr Innes has led vital research into HCV antiviral therapy.

Funded by a Foundation Fellowship, and through large population cohort data which included patients from HCV Research UK, Dr Innes has shown that antiviral therapy reduces risk of death and severe liver disease for HCV patients.

This data has influenced policymakers, instigating scale-up programmes for antiviral treatment, to work towards HCV elimination.

Despite improvements in treatment, people with HCV cirrhosis remain at high risk of dying from liver cancer after their HCV infection is cured. Most of these liver cancer deaths could be averted by detecting the liver cancer early when it is smaller, and therefore much easier to treat.

Dr Hamish Innes’ research is now exploring how clinical prediction models, like risk calculators, could improve early detection of liver cancer in patients with HCV.

Risk calculators are used widely by health professionals to generate a 'score' which estimates the likelihood of individuals developing certain diseases. These scores aid decision making in clinical practice and guide the type of treatments that health care professionals prescribe.

Dr Innes will use the Emerging Leaders Prize funding to access new datasets, allowing him to strengthen the evidence base for liver cancer surveillance in HCV patients and continue research into the genetic predictors of liver cancer.

Ultimately, Dr Innes’ ambition is to lead a data science team that will tackle the biggest challenges in liver disease and viral hepatitis over the next 25 years.

Dr Innes said : “It was absolutely amazing to win this Emerging Leaders Top Prize and hugely exciting in terms of my research. I still cannot believe it. It’s fantastic news and huge kudos, not just for me but for this University.

“I’m going to use the money to expand my access to date sets that have the potential to change practice and policy.

“This will be a launchpad to allow me to build my own data science team at the University. The vision would be to connect personalised medicine with liver disease and viral hepatitis, and put those two things together.

“About 16,000 people die in the UK from liver disease every year. Many of those deaths could be avoided. It’s not so much that we don’t have the right treatments, it’s that we are not able to target the treatments that we have to the right patients.

Personalised medicine is about considering patients as individuals and moving away from a one size fits all decision-making approach. We need more innovation and progress in this area.”

Dr Angela Hind, Chief Executive of the Medical Research Foundation, said: “ We want to continue making a difference to the study of hepatitis by supporting the research leaders of the future, and our 2023 Emerging Leaders Prize-winners are all making a significant impact in this field.

“By investigating the fundamental causes of hepatitis and the way we treat it, their research could lead to much-needed new approaches to diagnosis and treatment. In turn, these advances could significantly improve the lives of patients living with hepatitis and hepatitis-related illness.”

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

• Accessibility

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

30 November 2022

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Up to 50,000 people in the UK are thought to have lupus, a complex, long-term illness that can cause damage to the skin, organs, joints or any other part of the human body. While it can affect anyone, it is more common in those who are of African, Caribbean or Asian origin, and women account for 90 per cent of cases.

Funded by a generous gift in Will from Dr Erina Herrick, the 2022 Emerging Leaders prize awards a total of £220,000 to researchers from the University of Oxford, University of Liverpool, and University College London.

Dr Alex Clarke, Senior Clinical Research Fellow at the Kennedy Institute of Rheumatology was joint 1st place winner and receives £100k.

Alex's research aims to understand the fundamental causes of lupus, with the objective of identifying novel treatment targets. He studies how the metabolism of immune cells differs in autoimmunity, and how this contributes to the development of lupus.

When cells are deficient in energy, nutrients, or are stressed, they activate a recycling system called 'autophagy' to break down large molecules into smaller ones for fuel. Alex's work in lupus has shown that autophagy is activated in B cells, and is required for them to produce antibodies. His research group has now identified two new metabolic vulnerabilities in another B cell type, called germinal centre B cells, which are known to be dysfunctional in lupus. This body of work improves our understanding of lupus and helps to open new therapeutic avenues.

Thanks to the Emerging Leaders Prize, Alex will be able to study the metabolism of plasmacytoid dendritic cells in lupus. These cells are the main producers of a type of interferon that causes many of the symptoms and signs of lupus. If researchers can understand how cell metabolism is altered, they might be able to rebalance it and, as a result, develop new treatment approaches.

Other winners announced were Dr Eve Smith, NIHR Academic Clinical Lecturer, University of Liverpool and Alder Hey Children's NHS Foundation Trust who also receives £100k as joint winner, and Dr Thomas McDonnell, Medical Research Foundation Fellow, University College London receiving £20k as runner up.

Dr Angela Hind, Chief Executive of the Medical Research Foundation, said: "Lupus is poorly understood, difficult to diagnose and treat, and there is no full cure – all of which leaves a huge unmet need for new research. We're excited to be supporting the next generation of leaders in lupus research, as a tribute to Dr Erina Herrick, a scientist who lived with lupus for most of her life. Sometimes our donors specify areas of research important to them, and this was the case with Erina, who left a gift in her Will to support emerging research leaders in the field of lupus."

The prize-winners received their awards at a ceremony in London on Tuesday 29 November 2022.

Our research themes

• Clinical translation and experimental medicine
• Computational biology
• Immunity and microbes
• Inflammation biology
• Tissue remodelling and repair

Similar stories

Tom hosack awarded an mrc fellowship, university of oxford dphil student attends kenya reception at buckingham palace, new professor named at the kennedy, professor michael dustin elected to the royal society, professor michael dustin appointed new chair in molecular immunology, two prestigious hunterian professorships awarded to ndorms researchers.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

• Accessibility

David Eyre wins Medical Research Foundation Emerging Leaders Prize

21 November 2019

Dr David Eyre  at the Big Data Institute (BDI) has been named a runner up in the  Medical Research Foundation ’s third annual Emerging Leaders Prize, winning a £5,000 grant.

The Emerging Leaders Prize recognises outstanding scientists who are making a significant impact in the fight against antimicrobial resistance (AMR). Antibiotics are one of the great medical achievements of the 20 th  century, but their overuse and misuse have led to them becoming ineffective against an increasing number of microbes, posing a serious threat to human life. Drug-resistant infections are thought to cause 700,000 deaths annually across the world, a figure expected to rise to 10 million by 2050 with a cumulative cost of US$100 trillion.

Dr Eyre said: ‘Using this prize fund I will further develop state-of-the-art approaches to detecting infection which are faster than traditional methods that rely on waiting for bacteria to grow in the lab. In collaboration with my colleagues at the BDI, I will also combine these approaches with artificial intelligence techniques to predict which patients are most at risk of antibiotic resistance, and to pick the best antibiotics to use.’

He will base the new methods on DNA sequencing, to detect antibiotic resistance in patients with sepsis and other serious infections. Faster diagnosis will give patients earlier access to the right treatment, saving lives and preventing the spread of resistance by avoiding antibiotic overuse.

Dr Angela Hind, Chief Executive of the Medical Research Foundation, said: ‘We support exciting new research where there is high clinical need, and the increasingly serious threat of drug resistant infections to human lives clearly fits the bill. Through our Emerging Leaders Prize we’re looking for scientists on a trajectory to do something unique and special in their field, and that’s undoubtedly the case with our prize-winners. The prize fund is flexible, meaning the winners decide how best to use it. That could mean spending some time in a lab overseas, buying a cutting-edge piece of technology for their research, or investing in their personal career development.

‘We hope this prize will be transformative for our winners’ research and provide a springboard for the next stage of their careers.’

David is one of four researchers to be awarded Emerging Leaders Prizes this year.

UCL Department of Biochemical Engineering

• Collaborate
• News and events
• Equality Diversity & Inclusion

Thomas McDonnell wins Medical Research Foundation Emerging Leaders Prize

30 November 2022

UCL Biochemical Engineering Research Fellow Dr Thomas McDonnell (pictured below right) is one of three exceptional lupus researchers to have been announced as winners of the Medical Research Foundation’s 2022 Emerging Leaders Prize.

Funded by a generous gift in Will from Dr Erina Herrick, the 2022 prize awards a total of £220,000 to researchers from the University of Liverpool, University of Oxford, and University College London.

Up to 50,000 people in the UK are thought to have lupus, a complex, long-term illness that can cause damage to the skin, organs, joints or any other part of the human body.

Find out more

• Read the full story on the MRC website here
• Dr Thomas McDonnall's research group

Related News

Stanford Cancer Institute

Search stanford cancer institute, the mark foundation emerging leader awards.

Deadline: April 29, 2024

The Mark Foundation for Cancer Research  Emerging Leader Awards  support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. Read about recent Emerging Leader Award grantees  here . Here are some details about this call for proposals:

• The awards are $750,000 total over a three-year term, beginning January 1, 2025.
• Applicants must be three to eight years from the start of an independent faculty research appointment (start date must fall within 2016-2021). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis.
• Applicants must be employed by a U.S. or Canadian non-profit academic institution.
• Letters of intent will be accepted through 5 PM Eastern Time on Monday, April 29, 2024.

Visit thier  website  for complete details and submission guidelines.

Patient Care

Clinical trials, health equity, shared resources, stanford medicine, health care.

©2024 Stanford Medicine

2022 Emerging Leaders Prize Awarded to 3 Researchers in UK

Awardees received a total of £220K funded by the will of scientist with the disease

by Patricia Valerio, PhD | December 8, 2022

Share this article:

The Medical Research Foundation has awarded its sixth Emerging Leaders Prize to three lupus researchers in the U.K.

The scientists received a total of £220,000 (around $269,000), funded by a gift in the will of Erina Herrick, a scientist with the disease who devoted her research to it.

“We’re excited to be supporting the next generation of leaders in lupus research, as a tribute to Dr Erina Herrick, a scientist who lived with lupus for most of her life,” Angela Hind, PhD, the foundation’s chief executive, said in a press release . 

“Sometimes our donors specify areas of research important to them, and this was the case with Erina, who left a gift in her Will to support emerging research leaders in the field of lupus,” Hind said.

Lupus Foundation Honors Scientists for Their Research Contributions

Up to 50,000 people in uk may have lupus.

In the U.K., up to 50,000 people are thought to have lupus. As an inflammatory autoimmune disease, the condition causes the body’s immune system to attack its own healthy cells, resulting in inflammation in different parts of the body.

The disease can affect anyone but is more common in people of African, Caribbean, or Asian origin. Women account for 90% of the cases.

Different factors can trigger lupus, and every patient is affected differently. In mild cases, symptoms involve rashes and joint problems, but in more severe ones, the disease can lead to kidney failure, heart disease, and neurological damage. 

Such a broad spectrum of symptoms common to other diseases makes diagnosing and treating lupus challenging. There is still no cure, but symptoms can ease if patients start treatment early.

“Lupus is poorly understood, difficult to diagnose and treat, and there is no full cure — all of which leaves a huge unmet need for new research,” Hind said.

The Medical Research Foundation seeks to support researchers studying the disease and trying to make a difference ultimately for patients.

We’re excited to be supporting the next generation of leaders in lupus research, as a tribute to Dr Erina Herrick, a scientist who lived with lupus for most of her life

2 researchers share top prize of £100,000 each

This year’s top Emerging Leaders Prize was awarded to two researchers, who each received £100,000 (around $122,000): Eve Smith, PhD, National Institute for Health and Care Research’s academic clinical lecturer at the University of Liverpool and Alder Hey Children’s NHS Foundation Trust; and Alex Clarke, PhD, Kennedy Institute of Rheumatology’s senior clinical research fellow at the University of Oxford.

Smith’s research has been focused on lupus in children. She leads an international program called TARGET LUPUS, which seeks to develop a new “treat-to-target”-based approach to patient management, promoting early aggressive treatment to prevent organ damage, reduce side effects, and improve survival.

The funding will help Smith speed up a long-term goal of developing clinical trials in lupus and other rare pediatric diseases with a focus on improving patient care, and supporting analysis for the program.

Clarke’s work seeks to understand the fundamental causes of lupus. He studies how the metabolism of immune cells changes in autoimmunity and how this can promote lupus development.

The award will help Clark further investigate metabolic alterations in cells involved in immunity and the possible development of new therapeutic strategies.

Lupus Foundation of America Grants Fellowships for 6 Young Scientists

Third prize goes to young scientist studying antiphospholipid syndrome and lupus.

The third award was given to Thomas McDonnell, PhD, Medical Research Foundation fellow at University College London, who received £20,000 (around $24,468).

McDonnell’s research focuses on antiphospholipid syndrome, a condition that significantly overlaps with lupus. It corresponds to a hypercoagulable state induced by antibodies against phospholipids, a major component of all cell membranes.

McDonnell has focused on establishing a unique, multidisciplinary approach in translational research, putting together techniques from different fields and applying them to benefit patients.

This funding will allow McDonnell to participate in a leadership course and train other scientists working on lupus and associated conditions.

Over the last five years, the Medical Research Foundation has invested £1.5 million ($1.84 million) in lupus research, including three awards in 2017 for its first Emerging Leaders Prize, and four research fellowships in 2019.

About the Author

Recent Posts

• When the ‘ugly-wuggly’ signs of a lupus flare start peeking out
• FibroBiologics files for US patent of fibroblast technology to treat lupus
• FDA OKs Phase 1 study of two-component immunotherapy
• 3 tips for facing a change of seasons with lupus
• Plant-based raw food diet eases symptoms of SLE, Sjögren’s: Report

Recommended reading

UC San Diego gifted $1.6M to enhance lupus research, care

Research Alliance awards team $3M to study pediatric lupus nephritis

Lupus Research Alliance scores $400K in annual golf fundraiser

Medical Research Foundation's first Emerging Leaders Prize

Apr 2018: Dr David Hunt, a consultant at the Anne Rowling Clinic, has won first prize in the Medical Research Foundation's Emerging Leaders Prize.

Lupus is a serious autoimmune condition caused when the body's immune system attacks its own tissue. It is most common in young women but in rare cases can affect children.

Dr Erina Herrick made the first Emerging Leaders Prize possible when she left a generous gift to the Medical Research Foundation in her will. The prize is a tribute to Dr Herrick's own work as a scientist and the contribution she made to lupus research.

The annual prize aims to recognise and reward talented researchers who've already made a strong contribution to their field. Together the three winners' research considers lupus from three perspectives: its impact on the brain, the role of genetics and the autoimmune response. All are clinical academics, meaning that they run research projects and treat patients. 

Dr Hunt's research looks at how lupus can affect the brain at a molecular level. He runs a specialist clinic at the Anne Rowling Clinic dedicated to tackling complex forms of brain inflammation with an emphasis on lupus.

Brain disease in lupus is very poorly understood. I'm delighted to have won the Emerging Leaders Prize as it's a wonderful recognition of the work my lab, clinic and colleagues are doing to help understand and tackle this important problem. Our ability to develop treatments to prevent or treat brain disease in lupus is hampered by two problems. Firstly we understand very little of the molecular pathways which drive brain disease. Secondly we don't have good ways of measuring brain dysfunction in clinical trials. My group addresses both of these roadblocks, trying to decode the molecular pathway and develop practical biomarkers of brain disease.  Dr David Hunt

Other prize winners were Dr Tracy Briggs of the University of Manchester and Manchester University NHS Foundation Trust who wins £80k and Dr Edward Vital of the University of Leeds who will receive £20k. Dr Briggs focuses on the genetics of lupus, Dr Vital on the autoimmune elements.

Related links

Medical Research Foundation Emerging Leaders Prize

Dr David Hunt's profile

• Our Mission
• Programs Overview
• ASPIRE Award
• Drug Discovery Award

Emerging Leader Award

• Endeavor award
• Fellowships
• The Mark Foundation Centers
• In the Clinic
• Research Portfolio
• Partnerships
• Investments
• Newsletters

We are now accepting Letters of intent for the Emerging leader award. See below for submission instructions and the link to apply. Letters are due by April 29, 2024

Program overview.

The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

Eligibility

• MD, PhD, or equivalent is required.
• Applicants must be employed by a U.S. or Canadian non-profit academic institution.
• Applicants must be three to eight years from the start of an independent faculty research appointment as of December 31, 2024 (i.e., the official start date of the appointment must fall within the calendar years 2016-2021). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis.
• This award is not intended to be the main source of funding for the applicant’s laboratory. Applicants must demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review process.
• Projects for this award must be centered on evidence-based laboratory, data, and/or medical science.
• Proposed projects must not be supported by other sources of funding. Finalists will be asked to discuss any potential overlap with other current or pending awards during the interview.
• Only one submission per applicant is permitted.
• If selected, finalists must be available for virtual interviews in October 2024.
• The Mark Foundation for Cancer Research does not discriminate on the basis of race, color, religion, national origin, sex, gender identity, sexual orientation, age, disability or any other legally protected characteristics.

Award Terms

• The grant amount is $250,000 per year for three (3) years totaling $750,000.
• Indirect costs are not to exceed 10% of direct costs and are included in total.
• Emerging Leader Awards are granted to a single investigator; co-investigators are not permitted. The award may be used to support projects carried out with collaborators, who may provide letters of support.
• In Year 3, at The Mark Foundation’s discretion, select Awardees may be invited to apply for up to two (2) years of additional funding depending on project progress.
• The letter of agreement will include IP terms with a revenue sharing component.
• Award start date will be January 1, 2025.

Submission Process

• Letters of Intent must be submitted through the online application system no later than 5 PM Eastern Time on Monday, April 29, 2024 . Registration and email address verification are required. Notifications will be sent from the application system so please be sure these emails are not caught in spam filters.
• Project Title
• Project Summary: description of the proposed project, including a concise discussion of the rationale, experimental approach, innovation, and potential impact (350 words).
• Statement of Project Distinction: brief paragraph describing how the proposed project is unique from the main focus of the lab and prior research activities.
• Applicants will also be requested to provide a biosketch (NIH format or similar) and a list of current grants and other funding supporting the lab.
• The initial review process of the Letters of Intent will conceal the applicant’s name and institution. Please avoid citations and references to the applicant and institution name in the Project Summary and Statement of Project Distinction.
• After the Letters of Intent have been evaluated, full applications will be accepted by invitation only.

March 20, 2024……………………………………… Letter of Intent Portal Opens

April 29, 2024………………………………………… Letters of Intent Due by 5pm ET

Week of June 10………………………………………. Applications Invited

July 22, 2024…………………………………………… Applications Due by 5pm ET

Week of September 23……………………………….. Finalists Notified

Week of October 7, 2024…………………………… Virtual Interviews of Finalists

January 1, 2025………………………………………….. Grant Start Date

EXPLORE EMERGING LEADER AWARD

Decoding the Autoantibody ‘Reactome’ in Cancer Immunotherapy

2024 emerging leader award, aaron ring, md, phd, fred hutchinson cancer center.

Dissecting Photoreceptor Lineage Identity as a Tumorigenic Vulnerability in Pediatric Cancer

Paul northcott, phd, st. jude children’s research hospital.

Mechanisms of Androgen Mediated Immune Suppression

Amy moran, phd, oregon health and science university.

Ribonucleotide Processing in Telomere Maintenance and Integrity

Bret freudenthal, phd, university of kansas medical center.

Defining the Protein Regulome Targeted by Lactate and Other Central Carbon Oncometabolites

Edward chouchani, phd, dana-farber cancer institute.

Identification of Specific Dietary Fats that Fuel Cancer

2023 emerging leader award, lydia lynch, phd, brigham and women's hospital, harvard medical school.

• News Releases

Medical Research Foundation’s Emerging Leaders Prize recognizes future leaders in lupus research

Medical Research Foundation

Three exceptional lupus researchers have been announced today as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Funded by a generous gift in Will from Dr Erina Herrick, the 2022 prize awards a total of £220,000 to researchers from the University of Liverpool, University of Oxford, and University College London.

Up to 50,000 people in the UK are thought to have lupus, a complex, long-term illness that can cause damage to the skin, organs, joints or any other part of the human body.

Lupus can affect anyone, but it is more common in those who are of African, Caribbean or Asian origin, and women account for 90 per cent of cases.

The disease has been linked to a range of potential ‘triggers’, including hormonal changes, sunlight, viral infection, childbirth and strong medications. These triggers result in an irregular immune response, where the body’s own immune system attacks its healthy cells, resulting in inflammation. In mild cases this can cause rashes and joint problems, but in more severe cases, this inflammation affects major organs, resulting in kidney failure, heart disease and neurological damage.

Lupus is inherently difficult to diagnose and treat, due to the broad spectrum of symptoms associated with the disease, which are common to many other diseases and conditions. There is currently no cure, but symptoms can improve if treatment starts early.

The Foundation wants to make a difference to people living with lupus, by supporting research leaders of the future. Lupus is one of its longest-standing research priorities, with £1.5 million invested in new research over the last five years, including three awards as part of the first Emerging Leaders Prize in 2017, and four research fellowships , awarded in 2019.

The 2022 Emerging Leaders Prize-winners are all making a significant impact in lupus research. By investigating the fundamental causes of lupus, their studies could lead to much-needed new approaches to diagnosis and treatment. In turn, these advances could dramatically improve the lives of adults and children living with lupus.  

Joint 1 st place, £100,000: Dr Eve Smith, NIHR Academic Clinical Lecturer, University of Liverpool and Alder Hey Children’s NHS Foundation Trust.

Dr Eve Smith’s research focuses on lupus in children, which is more severe than adult-onset lupus. It has greater disease activity, frequent, early occurrence of permanent organ damage, and higher death rates. Despite advances in care, there is an urgent need for a structured, evidence-informed approach to patient management, to improve outcomes in young children with lupus.

Dr Smith is leading the international ‘TARGET LUPUS’ research programme, directly responding to this unmet need. TARGET LUPUS aims to develop, implement, and test a novel ‘treat-to-target’ based approach to care, promoting early aggressive disease control to prevent organ damage, minimise adverse effects from drugs, and improve survival.

Dr Smith leads an international taskforce of global experts in childhood-onset lupus. Together they have developed recommendations and ‘paediatric specific’ target definitions underpinning the ‘treat-to-target’ approach to childhood-onset lupus.

Dr Smith’s long-term aim is to develop clinical trials in this and other rare paediatric diseases, with parallel laboratory research programmes.

Funding from the Foundation will hugely accelerate the development of these clinical trials, which are aimed at improving patient care. The prize funding will support a biostatistician undertaking analyses informing the programme, and facilitate taskforce meetings to agree fundamental aspects of TARGET LUPUS.

Joint 1st place, £100,000: Dr Alex Clarke, Senior Clinical Research Fellow at the University of Oxford’s Kennedy Institute of Rheumatology.

Dr Alex Clarke’s research aims to understand the fundamental causes of lupus, with the objective of identifying novel treatment targets. He studies how the metabolism of immune cells differs in autoimmunity, and how this contributes to the development of lupus.

When cells are deficient in energy, nutrients, or are stressed, they activate a recycling system called ‘autophagy’ to break down large molecules into smaller ones for fuel. Dr Clarke’s work in lupus has shown that autophagy is activated in B cells, and is required for them to produce antibodies. His research group has now identified two new metabolic vulnerabilities in another B cell type, called germinal centre B cells, which are known to be dysfunctional in lupus. This body of work improves our understanding of lupus and helps to open new therapeutic avenues.

Thanks to the Emerging Leaders Prize, Dr Clarke will be able to study the metabolism of plasmacytoid dendritic cells in lupus. These cells are the main producers of a type of interferon that causes many of the symptoms and signs of lupus. If researchers can understand how cell metabolism is altered, they might be able to rebalance it and, as a result, develop new treatment approaches.

Highly commended, £20,000: Dr Thomas McDonnell, Medical Research Foundation Fellow, University College London.

Dr Thomas McDonnell’s research focuses on the antiphospholipid syndrome; a condition which overlaps significantly with lupus, both in patients and underlying mechanisms.

His work has ranged from developing a potential new treatment, to studying Beta-2-Glycoprotein I (B2GPI), which represents the main autoantigen in antiphospholipid syndrome. To do this, Dr McDonnell has focused on developing a unique, multidisciplinary approach to translational research, incorporating techniques from multiple fields and bringing them to bear for the benefit of patients. This funding will allow Dr McDonnell to attend a leadership course and train other scientists working on lupus and associated conditions, helping to support the longer-term impact of his research. The funding will also be spent on introducing automation into Dr McDonnell’s lab, which will significantly extend the scope of his research.

Dr Angela Hind, Chief Executive of the Medical Research Foundation, said: “Lupus is poorly understood, difficult to diagnose and treat, and there is no full cure – all of which leaves a huge unmet need for new research. We’re excited to be supporting the next generation of leaders in lupus research, as a tribute to Dr Erina Herrick, a scientist who lived with lupus for most of her life. Sometimes our donors specify areas of research important to them, and this was the case with Erina, who left a gift in her Will to support emerging research leaders in the field of lupus.”

This is the sixth year of the Medical Research Foundation's Emerging Leaders Prize. In previous years, the Foundation has recognised researchers working in lupus, adolescent mental health, antimicrobial resistance, pain, and COVID-19. In 2023, the Prize will be open to researchers working in viral and autoimmune hepatitis.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

You are using an outdated browser. This page doesn't support Internet Explorer 6, 7 and 8. Please upgrade your browser or activate Google Chrome Frame to improve your experience.

Special Issue

Emerging leaders in dystonia research.

• Submission closed.

About this Special Issue

This Special Issue highlights the contributions of emerging leaders and investigators, primarily research and clinical fellows, recently funded by the Dystonia Medical Research Foundation (DMRF), whose work advances our understanding of the fundamental features ...

This Special Issue highlights the contributions of emerging leaders and investigators, primarily research and clinical fellows, recently funded by the Dystonia Medical Research Foundation (DMRF), whose work advances our understanding of the fundamental features of dystonia. The articles featured in this collection support progress in quickly recognizing different clinical presentations of dystonia, particularly where it co-occurs with other conditions or symptoms, and responding with effective personalized treatment plans for patients. Submission to this volume is by invitation only. We welcome invited current and former DMRF fellows in the movement disorder field with an emphasis on dystonia to submit papers on topics including, but not limited to: • Deep brain stimulation • Genetics of dystonia • Developments in diagnosing dystonia • Therapeutic protein targets • Brain imaging • Brain networks • Biomarker and wearable sensing • Treatment and clinical studies For invited authors, please view the information on our Author Guidelines , and for any inquiries, send an e-mail to: [email protected]. Manuscript Deadline: 30 May 2023 Two Special Issue Editors declare affiliations with DMRF. Jan Teller is Chief Scientific Advisor for DMRF. Aasef Shaikh is a member of the Medical & Scientific Advisory Council of DMRF.

Keywords : Dystonia, Movement Disorders, Biomarkers, Neurology, Deep Brain Stimulation

Recent Articles

Issue editors, participating journals.

• Demographics

No records found

total views article views article downloads topic views

Top countries

Top referring sites.

Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection

Collaborators.

• Sechenov StopCOVID Research Team : Anna Berbenyuk ,  Polina Bobkova ,  Semyon Bordyugov ,  Aleksandra Borisenko ,  Ekaterina Bugaiskaya ,  Olesya Druzhkova ,  Dmitry Eliseev ,  Yasmin El-Taravi ,  Natalia Gorbova ,  Elizaveta Gribaleva ,  Rina Grigoryan ,  Shabnam Ibragimova ,  Khadizhat Kabieva ,  Alena Khrapkova ,  Natalia Kogut ,  Karina Kovygina ,  Margaret Kvaratskheliya ,  Maria Lobova ,  Anna Lunicheva ,  Anastasia Maystrenko ,  Daria Nikolaeva ,  Anna Pavlenko ,  Olga Perekosova ,  Olga Romanova ,  Olga Sokova ,  Veronika Solovieva ,  Olga Spasskaya ,  Ekaterina Spiridonova ,  Olga Sukhodolskaya ,  Shakir Suleimanov ,  Nailya Urmantaeva ,  Olga Usalka ,  Margarita Zaikina ,  Anastasia Zorina ,  Nadezhda Khitrina

Affiliations

• 1 Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 2 Inflammation, Repair, and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom.
• 3 Soloviev Research and Clinical Center for Neuropsychiatry, Moscow, Russia.
• 4 School of Physics, Astronomy, and Mathematics, University of Hertfordshire, Hatfield, United Kingdom.
• 5 Biobank, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 6 Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 7 Chemistry Department, Lomonosov Moscow State University, Moscow, Russia.
• 8 Department of Polymers and Composites, N. N. Semenov Institute of Chemical Physics, Moscow, Russia.
• 9 Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.
• 10 Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany.
• 11 Institute for Urology and Reproductive Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 12 Department of Intensive Care, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 13 Clinic of Pulmonology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 14 Department of Internal Medicine No. 1, Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 15 Department of Forensic Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• 16 Department of Statistics, University of Oxford, Oxford, United Kingdom.
• 17 Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
• 18 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
• 19 Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.
• 20 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
• PMID: 33035307
• PMCID: PMC7665333
• DOI: 10.1093/cid/ciaa1535

Background: The epidemiology, clinical course, and outcomes of patients with coronavirus disease 2019 (COVID-19) in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically diagnosed COVID-19 in real-life settings is lacking.

Methods: We extracted data from the medical records of adult patients who were consecutively admitted for suspected COVID-19 infection in Moscow between 8 April and 28 May 2020.

Results: Of the 4261 patients hospitalized for suspected COVID-19, outcomes were available for 3480 patients (median age, 56 years; interquartile range, 45-66). The most common comorbidities were hypertension, obesity, chronic cardiovascular disease, and diabetes. Half of the patients (n = 1728) had a positive reverse transcriptase-polymerase chain reaction (RT-PCR), while 1748 had a negative RT-PCR but had clinical symptoms and characteristic computed tomography signs suggestive of COVID-19. No significant differences in frequency of symptoms, laboratory test results, and risk factors for in-hospital mortality were found between those exclusively clinically diagnosed or with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR. In a multivariable logistic regression model the following were associated with in-hospital mortality: older age (per 1-year increase; odds ratio, 1.05; 95% confidence interval, 1.03-1.06), male sex (1.71; 1.24-2.37), chronic kidney disease (2.99; 1.89-4.64), diabetes (2.1; 1.46-2.99), chronic cardiovascular disease (1.78; 1.24-2.57), and dementia (2.73; 1.34-5.47).

Conclusions: Age, male sex, and chronic comorbidities were risk factors for in-hospital mortality. The combination of clinical features was sufficient to diagnose COVID-19 infection, indicating that laboratory testing is not critical in real-life clinical practice.

Keywords: COVID-19; Russia; SARS-CoV-2; cohort; mortality risk factors.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Publication types

• Observational Study
• Research Support, Non-U.S. Gov't
• Hospitalization
• Middle Aged

Grants and funding

• 20-04-60063/Russian Foundation for Basic Research

Find out about insurance programs, pay types, leave options, and retirement planning.

Discover resources to have a balanced career at NIH.

Resources for training to develop your leadership and professional skills.

Access your personnel information and process HR actions through these systems.

Information for managers to support staff including engagement, recognition, and performance.

Discover what’s next at the NIH.

2024 NIH Director’s Awards Guidelines

Nih director's awards nominations.

The NIH Director’s Awards are intended to recognize exceptional performance or special efforts significantly beyond regular duty requirements and are directly related to fulfilling the NIH mission. Nominations are submitted for specific categories according to the nature of the act, service, or work performance. Please contact your IC Award Coordinator for details on how to submit a nomination.

General Guidelines

These guidelines apply to the award categories for the NIH Director's Awards.

• Scientific/Medical Award - Research

All NIH employees, staff, or groups of staff (which can also include contractors) performing research, administering clinical/scientific disciplines, or working in scientific research professions.

Eligibility and nomination criteria

• Scientific/Medical Award - Clinical Care

All NIH employees, staff, or groups of staff (which can include contractors) who provide exceptional patient care.

• Administrative Award

All NIH employees, staff, and groups of staff (which can also include contractors) performing, administering, or working in administrative functions.

• Common Fund Leadership

All NIH employees promoting the advancement of the NIH Common Fund Program initiatives and/or their underlying processes.

• Common Fund Unsung Heroes Award

All NIH employees who are involved with the management of Common Fund programs.

• Customer Service Award

The purpose of this award is to recognize NIH employees who deliver exceptional customer service. The award recognizes those individuals or groups whose professionalism, and commitment to customer service make them role models for customer service delivery.

• Emerging Leader Award

The award recognizes NIH employees who show exemplary promise as future leaders, who may not necessarily be in a formal leadership role (i.e., supervisor or manager). 

Mission Support

All NIH employees, staff, and groups of staff (which can also include contractors) in grades GS-1 through GS-12 or equivalent performing activities that support ongoing maintenance, office support, and infrastructure of NIH. Nominations must not have employees in grades GS-13 or above, with the exception of a single team lead for a group that otherwise meets that grade limit.

• Ruth L. Kirschstein Mentoring Award

This award is designed to support and encourage the continuation of mentoring activities within the organization and to establish mentoring as a core value at the NIH. The award is given to individuals who have demonstrated exceptional leadership, skill, and ability in serving as a high-quality mentor to one or more individuals.

• Alan S. Rabson Award for Clinical Care

This award is to recognize outstanding clinical researchers who have demonstrated an exceptional commitment to assisting patients and their families who look to the National Institutes of Health for help. Recipients of this award exemplify Dr. Rabson’s unswerving commitment to scientific and technical excellence, collaboration with colleagues, and provision of excellent, compassionate care for patients and those who love them.

The NIH Work/Life and Well-Being Champion

This award is intended to recognize one supervisor’s exceptional performance or special efforts in supporting their employees’ work/life and well-being while maintaining or improving productivity in support of the agency’s mission.

Awards Navigation

• 2024 General Guidelines
• Mission Support Award
• NIH Work/Life and Well-Being Champion

Contact us to ask a question, provide feedback, or report a problem.

• Partner with us
• Apply Online

Pirogov Medical University

The university.

• Recognitions
• Eligibility
• Fees Structure

Founded in 1906 in the city of Moscow, Pirogov Medical University—officially known as Russian National Research Medical University named after N. I. Pirogov— is one of the oldest medical universities in Russia.  The first lecture took place on September 26, 1906, with 206 students, and the first graduation ceremony was celebrated in 1912. The University claims to be the first university in Russia that started offering medical education to women in the Russian Federation.It independently carries out various research projects in medicine and has received the status of National Research University in 2010.The Library of Pirogov Medical University has a collection of more than 7,50,000 books. For world-class clinical training and diverse practical exposure, the University collaborates with more 120 hospitals across the city of Moscow. Pirogov Medical University started accepting international students in 1959. Presently, more than 8,000 students are studying medicine at the University, out of which about 700 are international students.  The University has a strong team of about 2,000 faculty members. Pirogov Medical University is approved by the Medical Council of India (MCI) and offers a 6-Year Program for MBBS in Russia. Students in India, who have qualified NEET, can apply for direct admission to the MBBS Program of Pirogov Medical University.

Ministry of Science and Higher Education, Russia

World Directory of Medical Schools (WDOMS)

Medical Council of India (MCI)

Foundation for Advancement of International Medical Education and Research (FAIMER)

To get admission to the MBBS Program of Pirogov Medical University, the student must qualify NEET-UG (National Eligibility cum Entrance Test-Undergraduate). 

Besides NEET-UG, there is no requirement to go through any additional entrance examination.

RUS EDUCATION SUPPORT

INDIAN FOOD

MODERN CLASSROOMS

Medical Laboratories

Clinical Training

Recreational Facilities

Ensured Safety

FMGE (Foreign Medical Graduates Examination) Preparation

USMLE (United States Medical Licensing Examination) Preparation

• Pirogov Medical University was founded in 1906 in the Moscow city of Russia.
• In 1930, Pirogov Medical University organized the World’s first pediatric faculty.
• In 1963, Pirogov Medical University organized the World’s first biomedical faculty.
• In 2010, Pirogov Medical University received the status of National Research University.
• Presently, more than 8,000 students are studying at Pirogov Medical University, out of which about 700 are international students.

University Address

Mbbs program, admission & support, medical licensing examination support, student life.

Founded in 1906 in the city of Moscow, Pirogov Medical University—officially known as Russian National Research Medical University named after N. I. Pirogov— is one of the oldest medical universities in Russia.  The first lecture took place on September 26, 1906, with 206 students, and the first graduation ceremony was celebrated in 1912. 

Focused on constantly improving the quality of education, the University entered the list of Times Higher Education World University Rankings and QS World University Rankings in 2019. 

The University claims to be the first university in Russia that started offering medical education to women in the Russian Federation. Among all milestones achieved by the University, two most celebrated achievements are that Pirogov Medical University created the world’s first pediatric faculty in 1930 and the world’s first biomedical faculty in 1963.

To provide students and visitors a glimpse into the decades of the glorious history of the University, Museum of the History of Pirogov Medical University was established in 1981, which continues to capture astonishing achievements of the University, its students, and members.

The University maintains a leading position in Russia by actively participating in activities of medical research and healthcare and delivering excellence in medical education and care. 

The University independently carries out various research projects in medicine and has received the status of National Research University in 2010. Conducting pre-clinical as well as clinical studies for a better understanding of human diseases, new medicines, and medical devices have been the center of research at Pirogov Medical University.  

To keep the students and healthcare professionals updated on the latest research and innovations in medicine, the University publishes its own scientific journal with articles on biomedical sciences and clinical medicine.

The Library of Pirogov Medical University has a collection of more than 7,50,000 books. Students can also access scientific journals and eBooks through the electronic library system. In collaboration with other universities, academic mobility and exchange programs are also arranged for students to help them get experience in other institutions and build new connections.

For the healthcare of locals, the University operates clinical centers in Moscow. Students are provided hands-on clinical training in these University-operated clinics and also involved in various clinical studies. For world-class training and diverse practical exposure, the University collaborates with more 120 hospitals across the city of Moscow.

Pirogov Medical University started accepting international students in 1959. Until now, the University has trained more than 80,000 doctors. Presently, more than 8,000 students are studying medicine at the University, out of which about 700 are international students.  The University has a strong team of about 2,000 faculty members.

Pirogov Medical University is listed in the World Directory of Medical Schools (WDOMS) and certified by the Educational Commission for Foreign Medical Graduates (ECFMG), United States of America. Pirogov Medical University is also approved by the Medical Council of Canada (MCC) and the Medical Council of India (MCI). The University offers a 6-Year Program for MBBS in Russia for local as well as international medical aspirants. Students in India, who have qualified NEET, can apply for direct admission to the MBBS Program of Pirogov Medical University.

Pirogov Medical University Faculty of Medicine 1 Ostrovityanov Str Moscow, 117997 Russian Federation

Pirogov Medical University offers a 6-Year MBBS Program in the Russian language. For international students, classes for initial years may be organized in English medium.

The Program for MBBS in Russia is focused on building a strong academic base with a pragmatic approach to education and medical research. To provide hands-on clinical experience, the students studying MBBS in Russia are involved in clinical training from the second year of MBBS. While education in classrooms and laboratories helps the students develop academic skills and sound theoretical understanding, clinical training in University-affiliated hospitals help them apply their knowledge into practice.

To get admission to the MBBS Program of Pirogov Medical University, you can apply online at Rus Education website.

Rus Education is duly authorized by the Russian Centre for Science and Culture (Cultural Department of The Embassy of the Russian Federation in India) to promote Russian Education among Indian Citizens. Rus Education is also an authorized associate of Pirogov Medical University. We facilitate one-window admission to the MBBS Program of Pirogov Medical University with no requirement of any donation or capitation and without any entrance examination.

Pirogov Medical University offers a healthy student life and an opportunity to experience life in Moscow, the capital city of Russia, and also the most vibrant and exciting location in the largest country in the world! 

For affordable accommodation of students and make their living experience safe and better, the University maintains a comfortable dormitory. Every room is shared by two or three students, and each floor has a shared kitchen where students can cook their food. Members of the dormitory help the newcomers to settle in their new homes. For the safety of the students, the University’s security team maintains 24-hour surveillance and is capable of providing emergency response, if required.

To help students adjust to life at university, it has a dedicated Student Support System in place. Every group of new students is assigned to two professors who guide the students not only about studying but about living as well, helping students adjust to the new environment and feel comfortable.

To keep students fit and active, Sports Center on the campus is equipped with facilities to play various sports, including badminton, basketball, volleyball, table tennis, swimming, football, hockey, chess, etc. Student can unleash their creativity by indulging in extracurricular adventures offered by Student Organizations and Societies. On the campus, there are ample opportunities for self-improvement and taking part in music, dance, sports competitions, and theater. 

For peer support, the University has a Student Council in place which offers support in academic as well as non-academic matters making student life stress free.

For the social upliftment and help students connect with the society and local people, they are involved in community and welfare organized by the University, including medical outreach, health awareness programs, and blood donation camps.  The University Volunteer Center organizes a number of volunteer activities to help students contribute to social causes.

Living in Moscow, students can explore its cultural heritage, museums, historic buildings, the world-famous Alexander Garden, and much more. For traveling in Moscow, students don’t face any problems, thanks to its convenient and cheap transportation system, especially the Moscow Metro.

With the charm of Moscow and all the student facilities and support services offered by the University, student life at Pirogov Medical University is a delight.

TOP MEDICAL UNIVERSITIES IN RUSSIA

Perm State Medical University

Tver State Medical University

Orenburg State Medical University

Mari State University

Siberian State Medical University

A php error was encountered.

Severity: Notice

Message: Undefined variable: countries

Filename: includes/footer.php

Line Number: 26

File: /home/mbbsinrussia/public_html/application/views/includes/footer.php Line: 26 Function: _error_handler

File: /home/mbbsinrussia/public_html/application/controllers/University.php Line: 46 Function: view

File: /home/mbbsinrussia/public_html/index.php Line: 315 Function: require_once

Severity: Warning

Message: Invalid argument supplied for foreach()

Message: Undefined variable: state

Line Number: 44

File: /home/mbbsinrussia/public_html/application/views/includes/footer.php Line: 44 Function: _error_handler

©2024-25 Rus Education.